Moreover, CLL sub-clones carrying specific TP53 mutations can be positively selected upon treatment, ultimately becoming the prevalent expansion of an initially minor mutant component (69, 82–84). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.